Prognostic signatures in colon cancer

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Gestational trophoblastic disease tumours in high risk patients

State of PARP inhibitors and anti-angiogenics

Defining and advancing individualised medicine

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype

Putting the theory of personalised medicine into practice

Personalised cancer medicine and research: Today’s best practice

Too few women being offered breast-conserving treatment?

Molecular stratification of breast cancer: reaching the clinic

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)